Review of 2006, Stars of 2007

Article

Its almost time to close the door on 2006 and welcome another new year. But, before we do that we wanted to take you on a journey through the highs and lows of the past twelve months by reflecting on some of the most significant events to shape your industry this year.

It's almost time to close the door on 2006 and welcome another new year. But, before we do that we wanted to take you on a journey through the highs and lows of the past twelve months by reflecting on some of the most significant events to shape your industry this year.

On the subject of new therapies, this year also saw the approval of several new and exciting intraocular pressure (IOP) lowering drugs for glaucoma patients. It seems that researchers have now recognised the benefits of combining therapies with different mechanisms of action to bring about a more powerful effect than one therapy alone. Predicted to supersede unfixed combinations of drugs when dual therapy is necessary in glaucoma patients, the new fixed combinations have been reported to induce less side effects whilst being more convenient for the patient, hence aiding patient compliance. Here, we speak with Dr Thierry Zeyen of University Hospital Leuven in Belgium about what he thought were the highlights of 2006 and how he anticipates the glaucoma industry will shape up next year.

Meanwhile, this year has seen many reports on the benefits of refractive lens exchange in certain patient populations, particularly the mixing and matching of multifocal lenses to bring about clear vision. Whether this modality of treatment will be accepted in 2007, remains to be seen, but it certainly has caused a stir over the past 12 months.

In cataract surgery, the trend towards smaller incisions and the instruments that will aid microincision cataract surgery continued to make a splash. It is now accepted that small incision surgery will be the future of cataract surgery practice, with IOLs that can be implanted through these small incision looking likely to dominate the future IOL market.

In the pages that follow, we review some of the major events of 2006 and provide some insight into what you might expect in 2007. We also spotlight some of the products that made their way into your practice this year. Although by no means a fully comprehensive list, we aim to offer you a taste of what is currently out there and what you can expect to see materializing in your own practice during what promises to be an exciting new year.

We would like to say a very special thank you to our guest contributors: Dr Albert Augustin, Dr Thierry Zeyen and Dr Erik Mertens.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
© 2025 MJH Life Sciences

All rights reserved.